Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure Academic Article uri icon

Overview

MeSH Major

  • Heart Diseases
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha

abstract

  • Treatment with etanercept for 3 months was safe and well-tolerated in patients with advanced heart failure, and it resulted in a significant dose-dependent improvement in LV structure and function and a trend toward improvement in patient functional status.

publication date

  • February 27, 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11222463

Additional Document Info

start page

  • 1044

end page

  • 7

volume

  • 103

number

  • 8